Current therapies for Pseudomonas aeruginosa
Current therapies for Pseudomonas aeruginosa
复制标题
DOI：
10.1016/j.ccc.2007.12.004
复制
发表时间：
2008-04-01
影响因子：
4.3
通讯作者：
Kanellakopoulou, Kyriaki
中科院分区：
文献类型：
--
作者：
Giamarellou, Helen;Kanellakopoulou, Kyriaki
基于铜绿假单胞菌的多药耐药菌株在全球范围内的流行，以及没有新的抗假单胞菌药物可用的事实，本文旨在研究对抗铜绿假单胞菌引起的感染的治疗方案，包括多药耐药菌株。本文主要集中在粘菌素，重新出现的老抗生素，具有显着的抗假单胞菌体外活性和多利培南，一个新的碳青霉烯，似乎是接近其全球市场。关于旧的抗假单胞菌抗生素已被广泛审查，只有新的方面，他们的使用被认为是在这篇文章。
Based on the worldwide prevalence of multidrug-resistant strains of Pseudomas aeruginosa and the fact that no newer antipseudomonal agents are available, this article aims to investigate therapeutic solutions for combating infections caused by P aeruginosa, including multidrug-resistant strains. The article focuses mainly on colistin, the re-emerging old antibiotic that possesses prominent antipseudomonal activity in vitro and on doripenem, a newer carbapenem that seems to be close to its global marketing. Regarding older antipseudomonal antibiotics that have been reviewed extensively, only newer aspects on their use are considered in this article.